Immunosuppression effect of paclitaxel liposome and therapeutic effect thereof on rheumatoid arthritis

An immunosuppressant and taxane technology, applied in the field of paclitaxel liposome immunosuppressive effect and its therapeutic effect on rheumatoid arthritis, can solve problems such as adverse reactions in patients

Inactive Publication Date: 2009-12-30
PEOPLES HOSPITAL PEKING UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the drugs used to treat such diseases are mainly disease-modifying antirheumatic drugs (DMARDs). Methotrexate and cyclophosphamide, which were initially us

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunosuppression effect of paclitaxel liposome and therapeutic effect thereof on rheumatoid arthritis
  • Immunosuppression effect of paclitaxel liposome and therapeutic effect thereof on rheumatoid arthritis
  • Immunosuppression effect of paclitaxel liposome and therapeutic effect thereof on rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1: Inhibitory effect of paclitaxel liposomes on XG-7 cell proliferation

[0013] Multiple myeloma cells XG-7 (a commonly used B cell line) were stored in liquid nitrogen for a long time and resuscitated before use. XG-7 cells were routinely cultured in RPMI1640 medium containing 10% newborn bovine serum, plus rhIL- 6 (3 ng / ml) stimulated growth. XG-7 cells in the logarithmic growth phase were divided into 5×10 5 each / ml and 100 μl / well were inoculated in a 96-well culture plate, and the drugs were formulated into 5 levels of doubling ratio dilution concentration gradients (diluted with 1 640 culture solution), and 3 parallel wells were set up for each concentration of drugs, and the other Set the drug-free and cell-free control group to culture in an incubator at 37°C, 5% CO2 and saturated humidity. After culturing for 24 hours, add 10ulCCK-8 to each well and continue culturing for 2 hours. The absorbance value at 450nm was detected by a microplate reader, and ...

Embodiment 2

[0019] Example 2: Immunosuppressive effect of different concentrations of paclitaxel liposomes on XG-7 cells

[0020] In order to explore the immunosuppressive effect of different concentrations of paclitaxel liposomes on XG-7 cells, XG-7 cells in logarithmic growth phase were divided into 5×10 5 each / ml and 100 μl / well were inoculated in a 96-well culture plate, and different concentrations of paclitaxel liposomes were added respectively (final concentrations were 1, 2.5, 5, 10, and 20 ng / ml), and 3 drug concentrations were used for each concentration. After 24 hours, the cell supernatant was collected in parallel wells, and the IgG content in the cell supernatant was detected by ELISA. It was found that when the paclitaxel liposome concentration was above 5ng / ml, the IgG content in the cell culture supernatant decreased significantly, and it was concentration-dependent. Compared with the control group, the difference was significant (p figure 2 .

Embodiment 3

[0021] Embodiment 3: Paclitaxel liposome liposome treats CIA rat

[0022] 6-week-old female Lewis rats were intradermally immunized with bCII at the base of the tail to establish a CIA model. A total of 36 affected mice were randomly divided into three groups, namely, 5% glucose injection (GS) blank control group, 2.5mg / kg paclitaxel lipid Body (PTX) treatment group and 1mg / kg methotrexate (MTX) treatment group. The GS and PTX groups were given intraperitoneal injection every other day, and the MTX group was given intraperitoneal injection every week. Continuous treatment for 4 weeks. Arthritis scores were scored twice a week and mouse paw volumes were measured once a week. At the end of the treatment, the rats were anesthetized for joint X-ray filming and scoring. Rats were sacrificed, and serum was collected for anti-CII antibody detection. The results show that compared with the blank control group, 2.5mg / kg paclitaxel liposome treatment can significantly inhibit the joi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention confirms the suppression effect of paclitaxel liposome on B cell proliferation and immunologic function, and the application of paclitaxel liposome on rat CIA treatment.

Description

technical field [0001] This study involves the inhibitory effect of paclitaxel liposome on B cell proliferation and immune function and its application in the treatment of rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic progressive joint destruction. So far, the cause of the disease is unknown, but the abnormal function of cellular immunity and humoral immunity is the central link of RA autoimmune response. There is a lack of effective drugs and means for the treatment of this disease. At present, the drugs used to treat such diseases are mainly disease-modifying antirheumatic drugs (DMARDs). Methotrexate and cyclophosphamide, which were initially used as antineoplastic drugs, are also used as immunosuppressants to treat autoimmune diseases, but many patients have adverse reactions. Discontinue due to intolerance. Paclitaxel is a secondary metabolite extracted from the yew plant. At present, i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/127A61K31/337A61P37/06A61P29/00A61P19/04
Inventor 栗占国赵义常志芳
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap